Investors Advised on Class Action Lawsuit Against REGENXBIO Inc. Following FDA Announcement

Investor Alert: Class Action Lawsuit Against REGENXBIO Inc.

Pomerantz LLP, a prominent law firm specializing in corporate law, has announced the initiation of a class action lawsuit against REGENXBIO Inc., known for its innovative gene therapies. This lawsuit, which is particularly relevant for investors who experienced financial losses, comes in light of significant developments related to the company's operations and regulatory issues.

Overview of the Lawsuit

The class action is set against the backdrop of claims that REGENXBIO and certain personnel may have engaged in securities fraud or other unlawful business practices. Investors who acquired REGENXBIO securities during the class period face a crucial deadline to demand representation as Lead Plaintiff in the case; they have until April 14, 2026, to take appropriate action. Interested investors are urged to reach out to contact person Danielle Peyton of Pomerantz LLP for further inquiries and to ensure they are included in the legal proceedings.

Triggering Events: FDA Announcements

The catalyst for this class action suit was a press release issued by REGENXBIO on January 28, 2026, which stated that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on their investigational gene therapy product RGX-111. This gene therapy targets MPS I (Hurler syndrome) and was undergoing clinical evaluation when a serious adverse event involving a neoplasm was reported in one participant of a Phase I/II study. Alongside RGX-111, FDA scrutiny also extended to RGX-121, which is under development for MPS II (Hunter Syndrome). Both therapies shared common characteristics that led to the regulatory decision to halt further testing.

Following this alarming news, REGENXBIO's stock price experienced a dramatic drop, plummeting by $2.40 per share, or a staggering 17.9%, bringing the closing value down to $11.01 per share on the same day. This sharp decline ignited concern among shareholders, prompting the class action lawsuit as many feared further financial implications.

Pomerantz LLP: A Leader in Class Action Litigation

Founded by legal visionary Abraham L. Pomerantz, the firm has a notable history of advocating for investors and victims affected by corporate misconduct and securities fraud. With over 85 years of experience, Pomerantz LLP has successfully obtained significant settlements in many high-profile class action cases, making it a trusted name in the legal community. Their commitment to fighting for the rights of investors is paramount, ensuring that victims receive the justice they deserve.

As the case progresses, impacted investors are encouraged to remain vigilant and proactive about their legal rights. Those wishing to explore their options in this class action or get more details on the allegations against REGENXBIO will find resources and additional information on the firm’s official website.

Moving Forward: Importance of Vigilance

The outcome of this class action lawsuit could set a significant precedent in corporate governance and investor protection within the biotechnology industry. It serves as a vital reminder for investors to be informed and proactive about potential securities violations that could affect their investments. For individuals who hold shares in REGENXBIO and are concerned about this situation, it is advisable to consult with legal experts to understand their standing and potential recourse as the developments unfold.

In conclusion, the class action lawsuit against REGENXBIO Inc. marks a pivotal moment for affected investors to seek justice and potentially recover losses associated with the alleged unlawful practices. Keeping an eye on the unfolding legal proceedings could provide critical insights and updates vital to safeguarding investor interests.